SUZHOU, China, June 11, 2021 /PRNewswire/ -- Suzhou Frontera
Therapeutics Co., Ltd. ('Frontera') starts manufacturing facility
construction in BioBay of Suzhou Industrial Park. Xinyan Li, President of Suzhou Frontera hosted,
leaders of SIP and bioBay, representatives of investors and other
guests participated this ceremony.
Ni Qian, Vice Director of Suzhou Industrial Park Administration
Committee (SIPAC), delivered a warm congratulatory speech on behalf
of SIPAC. Director Ni said, "Frontera is an innovative
international gene therapeutics company, bearing the mission of
bringing treatment solutions to patients with rare diseases in
China as well as in the world.
Suzhou Frontera has made rapid progress and remarkable
achievements, as several products have already been promoted to
preclinical animal experiment stage."
Dr. Dai Yong, Co-Founder and CEO
of Frontera, faraway in Boston
now, expressed his gratitude to the leaders of SIPAC and bioBay for
their strong support as well as the investors for their trust. Dr.
Dai pointed out that in today's world, the total amount of patients
with rare diseases caused by genetic genes has exceeded that of
AIDS and cancer. Rare diseases are not rare, but facing the
predicament of difficult diagnosis and lack of medicine. Over 95%
of rare diseases are in the lack of effective treatment. While the
gene therapy industry in China has
just started, the enterprises are facing great challenges in
optimizing production process and expanding the scale of
commercialization. Since its establishment, Frontera has rapidly
built up a strong team consisting of CMC upstream and downstream
processes, preclinical, IND application and clinical trial talents,
showing its amazing growth speed and development potential to the
outer world.
About Frontera
Frontera was established by Creation Capital and OrbiMed
Capital, which are well-known funds in biotech industry. Frontera's
product pipeline covers ophthalmology, blood, genetic and metabolic
neuromuscular diseases and so on. Relying on its leading scientific
research team and professionals with rich experience in innovative
drug R & D, clinical research, registration and production
management in China and
the United States, Frontera
already started to promote products to preclinical animal
experiment stage in less than one year. The construction of Suzhou
manufacturing facility has also been officially started.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/suzhou-frontera-therapeutics-starts-manufacturing-facility-construction-301310778.html
SOURCE Frontera Therapeutics